76-03-9

Applied Filters:

Keyword:'76-03-9'

Showing 1-14 of 14 results for "76-03-9" within Papers

Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.

Josué C Lima-Junior et al.

PloS one, 7(5), e36419-e36419 (2012-06-01)

The antibody response generated during malaria infections is of particular interest, since the production of specific IgG antibodies is required for acquisition of clinical immunity. However, variations in antibody responses could result from genetic polymorphism of the HLA class II

Genetic association of HLA-DQB1 and HLA-DRB1 polymorphisms with alopecia areata in the Italian population.

F Megiorni et al.

The British journal of dermatology, 165(4), 823-827 (2011-06-23)

Alopecia areata (AA) is a multifactorial disease characterized by hair loss especially from the scalp. As for other autoimmune conditions, the major histocompatibility complex (HLA) region is associated with AA susceptibility. To provide evidence for the association of specific HLA-DQB1

MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations.

Yongmei Chen et al.

Frontiers in bioscience : a journal and virtual library, 11, 3121-3128 (2006-05-25)

Brain arteriovenous malformations (BAVM) have high matrix metalloproteinase-9 (MMP-9) expression, the source of which is unclear. We hypothesized MMP-9 production might be due to inflammation in BAVM. Compared to control brain tissues (n = 5), BAVM tissue (n = 139)

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

Elias Jabbour et al.

Blood, 117(13), 3641-3647 (2010-12-16)

Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We

An Analysis of Clostridium difficile Environmental Contamination During and After Treatment for C difficile Infection.

Kerrie Davies et al.

Open forum infectious diseases, 7(11), ofaa362-ofaa362 (2020-11-19)

Lower Clostridium difficile spore counts in feces from C difficile infection (CDI) patients treated with fidaxomicin versus vancomycin have been observed. We aimed to determine whether environmental contamination is lower in patients treated with fidaxomicin compared with those treated with

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis.

Vidya S Limaye et al.

Rheumatology international, 32(3), 611-619 (2010-12-03)

The aim of this study was to determine the HLA and autoantibody associations of patients with histologically confirmed idiopathic inflammatory myositis (IIM). Serum and DNA were archived from South Australian patients with biopsy-proven dermatomyositis (DM), polymyositis (PM) and inclusion body

Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects.

Michael R DeBaun et al.

American journal of human genetics, 70(3), 604-611 (2002-01-29)

Beckwith-Wiedemann syndrome (BWS) is a congenital cancer-predisposition syndrome associated with embryonal cancers, macroglossia, macrosomia, ear pits or ear creases, and midline abdominal-wall defects. The most common constitutional abnormalities in BWS are epigenetic, involving abnormal methylation of either H19 or LIT1

A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.

Anne Väisänen et al.

Human pathology, 42(8), 1103-1111 (2011-02-22)

The objective of this immunohistochemical study was to explore the roles of Ki67 and p53 in conjunction with matrix metalloproteinase-2 and matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 in a series of 157 cases of skin

Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer.

Michael Pinkawa et al.

Urology, 82(4), 963-968 (2013-10-01)

To evaluate the effect of increasing experience on hydrogel dimensions, rectal dose, and acute toxicity, and to discuss important technical issues gained from this experience. Sixty-four consecutive patients with prostate cancer were included in this analysis (G1/G2 corresponding to first/second

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.

Akira Kawai et al.

The Lancet. Oncology, 16(4), 406-416 (2015-03-22)

Trabectedin binds to the minor groove of DNA and blocks DNA repair machinery. Preclinical data have shown that trabectedin also modulates the transcription of the oncogenic fusion proteins of translocation-related sarcomas. We aimed to assess the efficacy and safety of

Suppressive effects of peptide antibiotics against proliferation and cytokine production in mitogen-activated human peripheral-blood mononuclear cells.

Masaki Maeda et al.

Arzneimittel-Forschung, 61(12), 734-741 (2012-01-28)

Certain kinds of peptide antibiotics are suggested to have immunomodulatory effects; however, few studies have been carried out systemically to evaluate the antiproliferative effects of peptide antibiotics in human lymphoid cells. The suppressive efficacies of nine peptide antibiotics and seven

Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.

Maartje I Kester et al.

JAMA neurology, 71(7), 855-862 (2014-05-14)

It remains unclear if and how associations between cerebral small-vessel disease and Alzheimer disease (AD) pathology lead to cognitive decline and dementia. To determine associations between small-vessel disease and AD pathology. Cross-sectional study from January 2002 to December 2012 using

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S Kim et al.

The Lancet. Oncology, 14(13), 1326-1336 (2013-11-16)

Available preclinical and phase 2 clinical data suggest that the addition of cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), to chemotherapy might improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Martin Reck et al.

The Lancet. Respiratory medicine, 7(5), 387-401 (2019-03-30)

The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report

Page 1 of 1